Supported by
Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these patients.
By Gina Kolata
A new drug has essentially cured 1 in 5 patients with chronic hepatitis B infections, researchers reported on Thursday, a feat that has stymied scientists for years.
“It’s the first major advance in the treatment of chronic hepatitis B in decades,” said Dr. William Jarnagin, a surgeon and liver specialist at Memorial Sloan Kettering Cancer Center.
